Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2024, on Friday, May 10, 2024. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
北卡羅來納州達勒姆，2024年5月6日（GLOBE NEWSWIRE）——Humacyte, Inc.（納斯達克股票代碼：HUMA）是一家以商業規模開發普遍可植入的生物工程人體組織的臨床階段生物技術平台公司，將於2024年5月10日星期五發布截至2024年3月31日的第一季度財務業績。管理層將在美國東部時間上午 8:00 主持網絡直播和電話會議，提供公司和財務最新情況。
| Title: | Humacyte First Quarter 2024 Financial Results and Corporate Update |
| Date: | May 10, 2024 |
| Time: | 8:00 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13746046 (Conference ID) |
| Call me Feature: | Click Here |
| Webcast: | Webcast Link - Click Here |
| 標題： | Humacyte 2024 年第一季度財務業績和公司最新情況 |
| 日期： | 2024年5月10日 |
| 時間： | 美國東部時間上午 8:00 |
| 電話會議詳情： | 1-877-704-4453（美國投資者撥號） 1-201-389-0920（國際投資者撥號） 13746046（會議 ID） |
| 給我打電話功能： | 點擊這裏 |
| 網絡直播： | 網絡直播鏈接-點擊這裏 |
The webcast should be accessible 15 minutes prior to the conference call's start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company's website for at least 30 days.
網絡直播應在電話會議開始前 15 分鐘播出。直播結束後將提供網絡直播的重播，並將在公司網站的投資者專區播出至少30天。
About Humacyte
關於 Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm HAV for urgent arterial repair following extremity vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte, Inc.（納斯達克股票代碼：HUMA）正在開發一個顛覆性的生物技術平台，以提供可普遍植入的生物工程人體組織、先進的組織結構和器官系統，旨在改善患者的生活並改變醫學實踐。該公司開發和製造用於治療各種疾病、損傷和慢性病的無細胞組織。Humacyte最初的機會是HAV產品組合，目前正在進行鍼對多種血管應用的後期臨床試驗，包括血管創傷修復、血液透析的AV通路和外周動脈疾病。冠狀動脈旁路移植術、小兒心臟手術、1 型糖尿病治療以及多種新型細胞和組織應用的臨床前開發也在進行中。Humacyte的6mm HAV用於血液透析的AV，是第一款獲得美國食品藥品管理局再生醫學高級療法（RMAT）稱號的候選產品，也獲得了美國食品藥品管理局的快速通道稱號。Humacyte 的 6mm HAV 用於四肢血管創傷後的緊急動脈修復，也獲得了 RMAT 稱號。HAV 被美國國防部長指定爲治療血管創傷的優先項目。欲了解更多信息，請訪問 www.humacyte.com。
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte 投資者聯繫人：
喬伊斯·阿萊爾
LifeSci 顧問有限公司
+1-617-435-6602
jallaire@lifesciadvisors.cominvestors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
Humacyte 媒體聯繫人：
Rich Luchette
精準策略
+1-202-845-3924
rich@precisionstrategies.commedia@humacyte.com
Source: Humacyte, Inc
資料來源：Humacyte, Inc
譯文內容由第三人軟體翻譯。